Sauerbrei A, Prager J, Hengst U, Zintl F, Wutzler P
Institute for Antiviral Chemotherapy of the Friedrich Schiller University, Jena, Germany.
Bone Marrow Transplant. 1997 Sep;20(5):381-3. doi: 10.1038/sj.bmt.1700909.
Herpes zoster (HZ) is one of the most common complications after bone marrow transplantation (BMT) in children. Apart from treatment with antiviral drugs, effective prevention by active immunization with varicella-zoster virus (VZV) appears to be possible. In this study 15 patients were vaccinated with a live attenuated VZV vaccine (Varilrix) 12-23 months after BMT. The vaccine was well tolerated without adverse reactions. Chickenpox or HZ were not observed for up to 2 years after immunization. Eight out of nine seronegative patients seroconverted and in six virus-specific IgG could still be demonstrated 2 years later. The incidence of VZV diseases in 133 non-immunized children after BMT was 26.3%. Infections usually occurred within 18 months after BMT.